on all orders above $300.00

FREE Pills!

via4gra pills

for free with every order



Less than in your
local pharmacy

Search by letter:

Zocef (Ceftin)

Rating of sales:          


Zocef is used for treating bacterial infections (sinus, skin, lung, urinary tract, ear, and throat). It may also be used to treat Lyme disease and gonorrhea. Ceftin is a cephalosporin antibiotic. It works by interfering with the formation of the bacteria's cell wall so that the wall ruptures, resulting in the death of the bacteria.

Other names for this medication:
Altacef, Cefakind, Ceftin, Ceftum, Cefuroxime, Oratil, Pulmocef, Stafcure, Supacef, Zinacef

Similar Products:
Lorabid, Cefotan, Cefzil, Lorabid Pulvules, Mefoxin, Raniclor

30 pills
When you purchase you get a bonus:
Cialis Soft
Cialis Soft 20mg
or Viagra Soft
Viagra Soft 100mg

You can choose your bonus in the shopping cart before checkout.

   bonus pills



USD 4.16 per pill   -20% USD 155.93 USD 124.74 per 30 pills   Order now
60 pills
When you purchase you get a bonus:
Cialis Soft
Cialis Soft 20mg
or Viagra Soft
Viagra Soft 100mg

You can choose your bonus in the shopping cart before checkout.

   bonus pills



USD 3.84 per pill   -20% USD 288.23 USD 230.58 per 60 pills   Order now
90 pills
When you purchase you get a bonus:
Cialis Soft
Cialis Soft 20mg
or Viagra Soft
Viagra Soft 100mg

You can choose your bonus in the shopping cart before checkout.

   bonus pills



USD 3.79 per pill   -20% USD 426.43 USD 341.14 per 90 pills   Order now
120 pills
When you purchase you get a bonus:
Cialis Soft
Cialis Soft 20mg
or Viagra Soft
Viagra Soft 100mg

You can choose your bonus in the shopping cart before checkout.

   bonus pills



USD 3.72 per pill   -20% USD 557.55 USD 446.04 per 120 pills   Order now
180 pills
When you purchase you get a bonus:
Cialis Soft
Cialis Soft 20mg
or Viagra Soft
Viagra Soft 100mg

You can choose your bonus in the shopping cart before checkout.

   bonus pills



USD 3.60 per pill   -20% USD 810.34 USD 648.27 per 180 pills   Order now

Also known as:  Ceftin.


Zocef eye drops and eye ointment are used to treat bacterial eye infections. Eye infections are a common cause of conjunctivitis. In conjunctivitis, your eye becomes inflamed, feels gritty, and may water more than usual. The white of your eye may look red, and your eyelids can become swollen and stuck together with a discharge when you wake up in the morning. Only one eye may be infected to begin with, but it often spreads to both eyes.

Most cases of infective conjunctivitis clear within a few days without treatment. For more severe infections, or for infections which do not clear on their own, an antibiotic eye drop or ointment such as Zocef can be helpful.

Zocef works by helping to kill the bacteria which are causing the infection. It is available on prescription. You can also buy the drops and the ointment from a pharmacy, without a prescription, if it is for conjunctivitis in an adult or a child over 2 years of age. Do not use Zocef eye drops or ointment for a child under 2 years old, unless it has been prescribed by a doctor.


Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.

You may take Zocef tablets with or without meals.

Zocef oral suspension (liquid) must be taken with food.

Shake the oral liquid well just before you measure a dose. To be sure you get the correct dose, measure the liquid with a marked measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.

If you switch from using the tablet form to using the oral suspension (liquid) form of Zocef, you may not need to use the same exact dosage in number of milligrams. The medication may not be as effective unless you use the exact form and strength your doctor has prescribed.

Use this medication for the entire length of time prescribed by your doctor. Your symptoms may get better before the infection is completely treated. Zocef will not treat a viral infection such as the common cold or flu.

This medication can cause you to have false results with certain medical tests, including urine glucose (sugar) tests. Tell any doctor who treats you that you are using Zocef.


Seek emergency medical attention if you think you have used too much of this medicine. Overdose symptoms may include seizure (black-out or convulsions).


Store at room temperature between 15 and 30 degrees C (59 and 86 degrees F) away from moisture and heat. Keep container tightly closed. Throw away any unused medicine after the expiration date. Keep out of the reach of children.

Side effects

The most common side effects associated with Zocef are:

  • zocef dry syrup composition
  • zocef cv medicine
  • tab zocef 200
  • tablet zocef 125
  • zocef syrup uses
  • tab zocef 250
  • zocef medicine
  • zocef 250 mg
  • zocef antibiotic uses
  • zocef 250 dosage
  • zocef 500 tablets
  • tab zocef price
  • zocef 250 tablet price
  • zocef 250 medicine
  • injection zocef 750 mg
  • tab zocef uses
  • zocef syrup
  • zocef 250 mg injection
  • zocef drug
  • zocef 250 tab
  • zocef cv dry syrup
  • tablet zocef cv
  • zocef 750 mg
  • zocef cv 500 dosage
  • zocef antibiotic
  • zocef dry syrup
  • tab zocef cv 250
  • zocef tablet
  • tab zocef cv
  • zocef generic name
  • dose of zocef
  • zocef syrup dosage
  • zocef cv syrup
  • zocef dose
  • tablet zocef cv 500
  • zocef 500 mg use
  • zocef 500 dosage

Side effect occurrence does not only depend on medication you are taking, but also on your overall health and other factors.


Contact your doctor right away if stomach pain or cramps, severe diarrhea, or bloody stools occur during treatment or within several months after treatment with Zocef. Do not treat diarrhea without first checking with your doctor.

The tablet and oral suspension forms of Zocef are not equivalent. Do not substitute one for the other.

Zocef only works against bacteria; it does not treat viral infections (eg, the common cold).

Be sure to use Zocef for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The bacteria could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.

Long-term or repeated use of Zocef may cause a second infection. Tell your doctor if signs of a second infection occur. Your medicine may need to be changed to treat this.

Diabetes patients - Zocef may cause the results of some tests for urine glucose to be wrong. Ask your doctor before you change your diet or the dose of your diabetes medicine.

Hormonal birth control (eg, birth control pills) may not work as well while you are using Zocef. To prevent pregnancy, use an extra form of birth control (eg, condoms).

Lab tests, including liver function, kidney function, and complete blood cell count, may be performed while you use Zocef. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

Zocef should not be used in children younger 3 months; safety and effectiveness in these children have not been confirmed.

Pregnancy and breast-feeding: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Zocef while you are pregnant. Zocef is found in breast milk. Do not breastfeed while taking Zocef.

zocef 250 tablet price

The results indicate that the efficacy and tolerability of cefdinir, once or twice daily, and cefuroxime were comparable with no significant differences between the regimens used.

tab zocef uses

Both treatment regimens gave rise to similar alterations of the normal oropharyngeal microflora. In both groups, the amount of Streptococcus salivarius was significantly reduced (P < 0.05). The most common causative pathogens of acute otitis were S. pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. On the day of enrollment, approximately half of the patients, in both groups, were infected with more than one pathogen. The rate of infection or colonization with more than one potential pathogen was low on day 7 but recurred 2 weeks after treatment to similar levels as on day 0. The total number of patients with reinfection, recolonization or recurrence of pathogens on day 21 was 11/12 in the amoxycillin-clavulanate group and 4/7 in the cefuroxime axetil group. The most common beta-lactamase producer was M. catarrhalis.

zocef tablet

Amoxicillin remains the antibiotic of choice for initial empiric treatment of AOM, although the traditional dosage should be increased in patients at risk for drug-resistant S. pneumoniae. In cases refractory to high-dose amoxicillin, TMP/SMX should be prescribed if adherence to prior therapy seemed good or complete, or high-dose amoxicillin/clavulanate if adherence was incomplete or questionable. Ceftriaxone should be reserved as third-line treatment. The increasing prevalence of drug-resistant S. pneumoniae emphasizes the importance of alternative medical approaches for the prevention of OM, as well as judicious antibiotic use in established cases. Removal of modifiable risk factors should be first-line therapy for prevention of rAOM. We support the use of conjugate pneumococcal vaccine per guidelines for prevention of rAOM from the Advisory Committee on Immunization Practice of the Centers for Disease Control and Prevention, with consideration given to influenza vaccine for cases of rAOM that historically worsen during the flu season. Sulfisoxazole prophylaxis should be reserved for children who are immunocompromised, have concurrent disease states exacerbated by AOM, or meet the criteria of rAOM despite conjugate pneumococcal and influenza vaccination. Therapy should be intermittent, beginning at the first sign of an upper respiratory infection, and should continue for 10 days. The invasive nature and risks of anesthesia relegate myringotomy, tympanostomy tubes, and adenoidectomy to last-line therapies for rAOM.

zocef 250 mg injection

A total of 563 isolates (330 Escherichia coli, 142 Proteus mirabilis and 91 Klebsiella spp) was studied; MIC50/MIC90 of Cefditoren was 0.25/0.5 mg/L respectively, with 97.1% of the isolates being inhibited at 1 mg/L. All 12 strains producing ESBLs or AmpC enzymes were resistant to cefditoren. Susceptibility rates (%) for amoxicillin/clavulanic acid, cefuroxime axetil, cefotaxime, ciprofloxacin, trimethoprim/sulfamethoxazole and fosfomycin were 93.1- 94.1- 96.8-93.1-71.9 and 92.8% respectively. Cefditoren MIC was significantly higher in nalidixic/ciprofloxacin non-susceptible strains; resistance to cefditoren was not associated with resistance to mecillinam, fosfomycin nitrofurantoin and aminoglycosides. Multivariate analysis demonstrated history of urinary infection in the last two weeks or three months as risk factors for cefditoren resistance.

zocef antibiotic uses

The efficacy of cefuroxime axetil compared with phenoxymethylpenicillin (PcV) was studied in group A beta-haemolytic streptococci (GAS) culture-proven tonsillitis in children aged 3-12 years with a history of at least 1 episode of tonsillopharyngitis requiring antibiotic therapy during the previous 3 months. This was a comparative, randomized, investigator-blind, multicentre study. A total of 236 children received either cefuroxime axetil suspension or PcV syrup. Inclusion criteria were a positive, rapid, group A strep test verified by bacteriological culture and clinical signs and symptoms of tonsillopharyngitis. Cefuroxime axetil treatment gave a significantly higher bacteriological eradication rate and clinical cure rate than PcV. At day 2-5 post treatment the eradication rates were 99/114 (87%) for cefuroxime axetil vs 61/109 (56%) for PcV (p < 0.001). The clinical cure rates were 98/114 (86%) and 73/109 (67%) respectively (p < 0.01). Up to 21-28 days post-treatment, 9/114 (8%) cefuroxime axetil patients and 37/109 (34%) PcV patients were treatment failures or had recurrence/reinfection of GAS tonsillopharyngitis (p < 0.001). More than 90% of the patients who experienced bacteriological treatment failure at either the first or second follow-up had the same serotype isolated pre- and post-treatment. During the study period, 21/114 (18%) patients in the cefuroxime axetil group and 50/109 (46%) patients in the PcV group received additional antibiotics (p < 0.001). No serious adverse events were noted and the mild adverse events were equally distributed among the patients in the 2 study groups: 15% for cefuroxime axetil and 14% for PcV.

tab zocef cv 250

The arrival of new cephalosporins faces the clinician with an evergrowing confusion as to the drug of choice. The older agents (cephalexin, cephradine, cefadroxil and cefaclor) and the newer formulations cefatrizine and cefuroxime axetil are intensively used for treatment of mild and moderate infections. The oldest agents have a better pharmacokinetic profile but are less active against Gram-positives and Gram-negatives. Cefaclor, cefatrizine and cefuroxime axetil have improved in vitro activity against H. influenzae and/or against S. aureus and M. catarrhalis. However the mean free serum concentrations after proposed standard daily doses of cefaclor (3 x 250 mg/d), cefatrizine (2 x 500 mg/d) and cefuroxime-axetil (2 x 250 mg/d) are lower than those of the older cephalosporins. In comparison amoxicillin-clavulanate is equally efficacious, has a more reliable pharmacokinetic profile and is less expensive than cefaclor and cefuroxime axetil in a comparable dose (e.g. 3 x 500 mg/d).

zocef 500 tablets

A simple rapid spectrophotometric method has been developed for estimation of cefuroxime axetil from bulk drug and tablet dosage form by using 1-nitroso-2-napthol and sodium hydroxide. The method is based on the formation of yellow-orange coloured complex of drug with 1-nitroso-2-napthol having absorbance maxima at 424 nm. The Beer's law is obeyed in the concentration range of 10-50 mug/ml of the drug but more precisely it obeys in the range of 10- 30 mug/ml. The slope and intercept values are 0.0101 and 0.0838, respectively. Results of analysis of this method were validated statistically and by recovery studies. The method is applied to the marketed tablet formulation. Result of analysis of tablet formulation given as percentage of label claim +/-standard deviation is 99.17+/-1.57. The precision and accuracy was examined by performing recovery studies and was found to be 99.50+/-1.82. Sandell's correlation coefficient is calculated as 0.4434. The developed method is simple, sensitive and reproducible and can be used for routine analysis of cefuroxime axetil from bulk and tablet dosage form.

zocef syrup dosage

Retrospective case series.

zocef dry syrup composition

This investigation describes the development of an intragastric drug-delivery system for cefuroxime axetil. The 3(2) full factorial design was employed to evaluate contribution of hydroxypropyl methyl cellulose (HPMC) K4M/HPMC K100 LV ratio (polymer blend) and sodium lauryl sulfate (SLS) on drug release from HPMC matrices. Tablets were prepared using direct compression technique. Formulations were evaluated for in vitro buoyancy and drug release study using United States Pharmacopeia (USP) 24 paddletype dissolution apparatus using 0.1N HCl as a dissolution medium. Multiple regression analysis was performed for factorial design batches to evaluate the response. All formulations had floating lag times below 2 minutes and constantly floated on dissolution medium for more than 8 hours. It was found that polymer blend and SLS significantly affect the time required for 50% of drug release, percentage drug release at 12 hours, release rate constant, and diffusion exponent (P<.05). Also linear relationships were obtained between the amount of HPMC K100 LV and diffusion exponent as well as release rate constant. Kinetic treatment to dissolution profiles revealed drug release ranges from anomalous transport to case 1 transport, which was mainly dependent on both the independent variables.

Target Point Shipping Method Tracking Delivery Time Price
Worldwide shipping

Worldwide shipping

Registered Mail  Not trackable 14-21 business days USD 20.00 per order
EMS  Trackable, where available 5-9 business days USD 30.00 per order

Delivery time is:

Registered Mail - 14-21 business days, prices - USD 20.00, no signature is required on delivery.
EMS - 5-9 business days, prices - USD 30.00, signature is required on delivery.
Your order will be packed safe and secure and dispatched within 24 hours.

front back side

This is exactly how your parcel will look like (pictures of a real shipping item). It has a look of a regular private letter and does not disclose its contents. Size - 9.4x4.3x0.3 inches (24x11x0.7cm).

 Show Hide 
tab zocef 250 2017-01-27

Cefuroxime axetil Tavanic 1000 Mg , an orally absorbed pro-drug of cefuroxime was used to treat a mainly elderly group of patients with symptomatic urinary tract infections. The drug was clinically effective and the bacteriological short term and long term cure rates (55% and 48% respectively) comparable to those of other antibiotics. The study had to be terminated however after the development of three cases of antibiotic associated colitis. Studies of the pharmacokinetics of the drug in volunteers gave inconsistent results suggesting that there may be variable bioavailability of the compound.

zocef cv 500 dosage 2015-07-29

This study on the intestinal transport of beta-lactam antibiotics was undertaken to investigate the correlation between cellular transport parameters and the Septra 10 Mg bioavailability.

zocef tablet 2016-11-11

To assess the efficacy and tolerability of three antibiotic Kalixocin Medicine regimens in patients with acute exacerbation of chronic bronchitis.

tab zocef cv 2017-10-26

Organisms were isolated from the pretreatment Fulgram Suspension 400 Mg middle ear fluid specimens of 177 of 244 (73%) patients undergoing tympanocentesis, with the primary pathogens being Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis (37, 35 and 12% of isolates, respectively). Pathogens were eradicated or presumed to be eradicated in 92% (24 of 26), 84% (32 of 38) and 95% (36 of 38) of bacteriologically evaluable patients treated with CAE for 5 or 10 days or with AMX/CL, respectively. A satisfactory clinical outcome (cure or improvement) occurred in 69% (101 of 147), 70% (121 of 173) and 74% (131 of 177) of clinically evaluable patients treated with CAE (5 days), CAE (10 days) or AMX/CL, respectively. Treatment with AMX/CL was associated with a significantly higher incidence of drug-related adverse events than was treatment with CAE for either 5 or 10 days (P < 0.001), primarily reflecting a higher incidence of drug-related gastrointestinal adverse events (34% vs. 17 and 12%, respectively; P < 0.001), particularly diarrhea.

zocef medicine 2017-01-21

The problem of pharyngeal infections caused by beta-hemolytic streptococci of group A (BHSA) remains a challenge for both health providers and general medicine. The present paper was designed to provide the data suggesting the "reappearance" of a highly virulent BHSA infection and a rise in the frequency of its complications (such as acute rheumatic fever and toxic shock syndrome) and to substantiate the necessity of rational antibacterial therapy for the management of this pathology. The agents of choice for the Zocef Syrup Uses treatment of acute forms of BHSA (tonsillitis and pharyngitis) include penicillins (amoxicillin, benzathine-penicillin, phenoxymethyl penicillin) and cephalosporins of the first generation (cephadroxyl) as well as macrolids (spiramycin, azithromycin, roxithromycin, midecamycin, josamycin) for the patients who do not tolerate beta-lactam antibiotics. Inhibitor-protected penicillins (amoxicillin, clavulanate) or cephalosporins of the second generations (cefuroxime-axetil) should be prescribed to the patients presenting with chronic recurring BHSA characterized by the rather high probability of colonization of the site of infection by beta-lactamase producing microorganisms. Lincosamine-derived antibiotics, such as lincomycin and clindamycin, are reserved for the patients with acute and chronic BHSA (tonsillitis and pharyngitis).

zocef 250 tab 2017-12-19

Levofloxacin continues to demonstrate good clinical efficacy in the treatment of a range of infections, including those in which S. pneumoniae is a potential pathogen. Importantly, it has Clavulin 625 Mg efficacy in CAP similar to that of gatifloxacin and at least as good as that of the third generation cephalosporins. Extensive clinical data confirm the good tolerability profile of this agent without the phototoxicity, hepatic and cardiac events evident with some of the other newer fluoroquinolone agents. Levofloxacin therefore offers a unique combination of documented efficacy and tolerability, and provides an important option for the treatment of bacterial infections.

zocef 500 mg use 2015-11-18

Telithromycin, a new ketolide, exhibits potent Cephalexin Name Brand activity against respiratory pathogens, including resistant strains.

zocef 250 mg injection 2015-03-07

The pharmacokinetic parameters of cefixime were determined in healthy volunteers following oral administration of 200 mg cefixime as tablet, syrup and dry suspension, respectively. All three galenic formulations showed reliable absorption. Mean peak plasma concentrations amounted to 2.4-3.4 mg/l and were reached after 3.3-3.5 h. Mean terminal half-lives were 2.9-3.1 h. The mean areas under the plasma concentration-time curves ranged between 18 and 26 mg/l.h; 18-24% of the dose administered were recovered unchanged in the urine. The best bioavailability was obtained with the dry suspension followed by the tablet and the syrup. With respect to the ester pro-drug cephalosporins, cefuroxime axetil, cefetamet pivoxyl and cefotiam hexetil, cefixime exhibits higher plasma half-life Macrobid 200 Mg and area under the curve as well as, comparable absolute bioavailability but consistently lower urinary recovery which indicates higher non-renal clearance.

zocef dry syrup composition 2016-02-14

In a randomized, open-label, controlled, multicentre study, the clinical and bacteriological efficacy, safety and tolerability of oral gemifloxacin (320 mg once daily, 5 days) was compared with sequential intravenous (i.v.) ceftriaxone (1 g once daily, maximum 3 days) followed by oral cefuroxime axetil (500 mg twice daily, maximum 7 days) in adult hospitalized patients with acute exacerbations of chronic bronchitis (AECB) (n = 274). The clinical success rates at follow-up (21-28 days post-therapy) in the clinical per-protocol population (the primary endpoint) were 86.8% (105/121) for gemifloxacin vs. 81.3% (91/112) for ceftriaxone/cefuroxime (treatment difference = 5.5,95% CI -3.9,14.9). The corresponding clinical results in the clinical intention-to-treat (ITT) population were 82.6% (114/138) vs. 72.1% (98/136), respectively (treatment difference = 10.5,95% CI 0.7, 20.4).Thus, gemifloxacin Co Azithromycin 250 Mg had significantly higher clinical success rates than ceftriaxone/cefuroxime. The median time to discharge was 9 days in the gemifloxacin group vs. 11 days in the ceftriaxone/cefuroxime group (P = 0.04, Wilcoxon test). At follow-up, 120/138 (87.0%) gemifloxacin-treated patients had been discharged from hospital, compared with 111/136 (81.6%) ceftriaxone/cefuroxime-treated patients in the clinical ITT population. Both treatments were generally well tolerated and there was no significant difference between the treatment groups in the incidence or type of adverse events reported. A 5-day course of oral gemifloxacin was shown by this study to be at least equivalent to sequential i.v. ceftriaxone/cefuroxime axetil (for up to 10 days) in patients with AECB who require hospital treatment.